Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $44.9 million.

  • Akebia Therapeutics' Operating Expenses rose 2561.22% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year increase of 1176.1%. This contributed to the annual value of $147.5 million for FY2024, which is 1154.86% down from last year.
  • Akebia Therapeutics' Operating Expenses amounted to $44.9 million in Q3 2025, which was up 2561.22% from $38.5 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Operating Expenses ranged from a high of $88.8 million in Q1 2022 and a low of $35.3 million during Q2 2024
  • Moreover, its 5-year median value for Operating Expenses was $45.4 million (2023), whereas its average is $55.1 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Operating Expenses plummeted by 4888.69% in 2023, and later skyrocketed by 2561.22% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Operating Expenses stood at $75.4 million in 2021, then fell by 15.0% to $64.1 million in 2022, then crashed by 43.58% to $36.2 million in 2023, then grew by 11.84% to $40.4 million in 2024, then rose by 11.12% to $44.9 million in 2025.
  • Its Operating Expenses was $44.9 million in Q3 2025, compared to $38.5 million in Q2 2025 and $36.2 million in Q1 2025.